79330499 - EXOREPLACE

Information

• Trademark
• 79330499

• Source

• Serial Number

  79330499

• Registration Number

  6998492

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  July 23, 2021
  3 years ago

• Registration Date

  March 14, 2023
  a year ago

• Transaction Date

  July 22, 2023
  a year ago

• Status Date

  March 14, 2023
  a year ago

• Published for Opposition Date

  December 27, 2022
  2 years ago

• Location Date

  March 14, 2023
  a year ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  WOLD, BARBARA NIELSEN

• Attorney Docket Number

  EVOX 2206919

  Attorney Name

  Nancy Sabarra

  Law Office Assigned Location Code

  M50

• Owners

  • Evox Therapeutics Limited

Case File Statements

• GS0051: Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes in the form of a liquid solution or lyophilised preparation for therapeutic use for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for genetic therapy; medicine for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; Medical preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for medical purposes for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome for the treatment of genetic diseases, respiratory diseases, or cancer; biological reagents for medical use; biological preparations for medical purposes, namely, for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; mixed biological preparations for the prevention and treatment of infectious diseases; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutic agents for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
• PM0001: EXO REPLACE
• GS0441: Medical services; medical and pharmaceutical consultancy; medical diagnostics, namely, medical testing, monitoring, and reporting services for diagnostic or treatment purposes; medical analysis services for the diagnosis and treatment of persons and for the diagnosis and treatment of genetic diseases; medical examination services; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid, namely, medical services, medical and pharmaceutical consultancy, medical diagnostics, namely, medical testing, monitoring, and reporting services, medical analysis services for the diagnosis and treatment of persons and for the diagnosis and treatment of genetic diseases, medical examination services, medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases, medical screening, medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases, and medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
• GS0421: Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services; biological research; clinical research in the field of transformational therapeutics; providing medical and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; information, advisory and consultancy services relating to the aforesaid, namely, scientific, medical and pharmaceutical research and development services, pharmaceutical drug development services, research and development of pharmaceutical preparations, scientific research and analysis services, biological research, clinical research in the field of transformational therapeutics, providing medical and scientific research information in the field of filtration of exosomes from cultured cells or blood, scientific investigations for medical purposes, scientific laboratory services, medical laboratory services, laboratory research services relating to pharmaceuticals, research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders, biotechnology, pharmaceutical research and development and genetic science, laboratory diagnostics, namely, medical analysis services relating to the diagnosis and treatment of persons provided by medical laboratories

Case File Event Statements

• 7/22/2023 - a year ago

  26 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 6/27/2023 - a year ago

  25 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 6/27/2023 - a year ago

  24 - FINAL DISPOSITION PROCESSED Type: FIMP

• 6/14/2023 - a year ago

  23 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 3/14/2023 - a year ago

  22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 3/14/2023 - a year ago

  21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 12/27/2022 - 2 years ago

  20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/27/2022 - 2 years ago

  19 - PUBLISHED FOR OPPOSITION Type: PUBO

• 12/7/2022 - 2 years ago

  18 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 11/21/2022 - 2 years ago

  17 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 11/21/2022 - 2 years ago

  16 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 11/21/2022 - 2 years ago

  15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 11/21/2022 - 2 years ago

  14 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 11/21/2022 - 2 years ago

  13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 10/21/2022 - 2 years ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 10/21/2022 - 2 years ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 10/21/2022 - 2 years ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 5/10/2022 - 2 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 4/21/2022 - 2 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 4/21/2022 - 2 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 4/20/2022 - 2 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 4/19/2022 - 2 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 4/19/2022 - 2 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 1/11/2022 - 3 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 1/7/2022 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 1/6/2022 - 3 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR